230 / 1138
•
Phase NCIC CTG BR.25 II study
•
80 biopsy-proven, peripherally located, T1-3 N0 M0 NSCLC
•
(2006 to 2008, 17 Canadian institutions)
•
60 Gy in 15 fractions, using 3DCRT
. No inhomogeneity
correction or IMRT use, with fluoroscopy for motion evaluation
•
GTV= primary tumor only; PTV margin = 1.0 to 1.5 cm.
•
Primary endpoint: 2-year primary tumor control rate.
Hypofractionated, Conventional delivery
Cheung PC, JNCI 2014